Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study

Payer blocking of branded migraine medications was fairly common, affecting one in five patients and was broadly associated with increased healthcare utilization. These findings suggest that payer blocking may disproportionately impact patients according to race/ethnicity, household income, and educational attainment. Although effect sizes were small, the outcomes may provide useful hypotheses for understanding and addressing healthcare disparities in migraine [Correction added on January 31, 2026 after first online publication: typos errors are removed to ensure accuracy].